Efficacy of adalimumab for pediatric Vogt-Koyanagi-Harada syndrome.

Abstract

Pediatric Vogt-Koyanagi-Harada syndrome (VKH) is rare, with limited cases of corticosteroid-sparing immunosuppression use reported. A 15-year-old Hispanic girl was referred for bilateral intraocular inflammation. Her initial best corrected visual acuity (BCVA) was 20/30 in the right eye and 20/200 in the left eye, with granulomatous keratic precipitates, anterior chamber and vitreous cell, optic disc edema, and nummular depigmented chorioretinal lesions on examination consistent with VKH after an unrevealing work-up. Inflammation was recurrent despite oral prednisone and methotrexate. Adalimumab, a TNF-alpha inhibitor, led to rapid resolution of inflammation, successful dose reduction of prednisone and methotrexate, and final BCVA of 20/25 in the right eye and 20/40 in the left at 26-month follow-up.

• Authors: Abdallah Jeroudi, Sheila T Angeles-Han, Steven Yeh
• Journal: Ophthalmic surgery, lasers & imaging retina (Ophthalmic Surg Lasers Imaging Retina) 2014 Jul-Aug Vol. 45 Issue 4 Pg. 332-4 ISSN: 2325-8179 [Electronic] United States
• PMID: 25037015 (Publication Type: Case Reports, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
• Copyright: Copyright 2014, SLACK Incorporated.

Chemical References

• Anti-Inflammatory Agents
• Antibodies, Monoclonal, Humanized
• Adalimumab

Topics

• Adalimumab
• Adolescent
• Anti-Inflammatory Agents (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Female
• Humans
• Treatment Outcome
• Uveomeningoencephalitic Syndrome (drug therapy)